[go: up one dir, main page]

WO2006002106A3 - Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide - Google Patents

Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide Download PDF

Info

Publication number
WO2006002106A3
WO2006002106A3 PCT/US2005/021827 US2005021827W WO2006002106A3 WO 2006002106 A3 WO2006002106 A3 WO 2006002106A3 US 2005021827 W US2005021827 W US 2005021827W WO 2006002106 A3 WO2006002106 A3 WO 2006002106A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drugs
polysaccharide
delivery
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/021827
Other languages
English (en)
Other versions
WO2006002106A2 (fr
Inventor
David Platt
Eliezer Zomer
Anatole Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Pharmaceuticals Inc
Original Assignee
Pro Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc
Priority to JP2007518186A priority Critical patent/JP2008503583A/ja
Priority to CA002570570A priority patent/CA2570570A1/fr
Priority to EP05786102A priority patent/EP1765365A4/fr
Priority to BRPI0512394-1A priority patent/BRPI0512394A/pt
Publication of WO2006002106A2 publication Critical patent/WO2006002106A2/fr
Publication of WO2006002106A3 publication Critical patent/WO2006002106A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des polysaccharides ramifiés ligands chimiquement solubles ayant un poids moléculaire compris entre environ 50 kD et environ 200 kD combinés à un ou plusieurs agents thérapeutiques. L'invention concerne aussi des procédés relatifs à l'utilisation de ces éléments en combinaison avec au moins un médicament anticancéreux pour le traitement et la prévention de cancer malin, et enfin des procédés relatifs à l'utilisation de la composition considérée pour le traitement et la prévention de l'angiogenèse.
PCT/US2005/021827 2004-06-22 2005-06-21 Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide Ceased WO2006002106A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007518186A JP2008503583A (ja) 2004-06-22 2005-06-21 抗がん薬、抗血管形成薬、及び多糖類を共デリバリーするための組成物及び方法
CA002570570A CA2570570A1 (fr) 2004-06-22 2005-06-21 Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide
EP05786102A EP1765365A4 (fr) 2004-06-22 2005-06-21 Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide
BRPI0512394-1A BRPI0512394A (pt) 2004-06-22 2005-06-21 composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58195804P 2004-06-22 2004-06-22
US60/581,958 2004-06-22

Publications (2)

Publication Number Publication Date
WO2006002106A2 WO2006002106A2 (fr) 2006-01-05
WO2006002106A3 true WO2006002106A3 (fr) 2006-10-19

Family

ID=35782284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021827 Ceased WO2006002106A2 (fr) 2004-06-22 2005-06-21 Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide

Country Status (6)

Country Link
EP (1) EP1765365A4 (fr)
JP (1) JP2008503583A (fr)
CN (1) CN101267828A (fr)
BR (1) BRPI0512394A (fr)
CA (1) CA2570570A1 (fr)
WO (1) WO2006002106A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
BRPI0911960B1 (pt) 2008-05-14 2022-03-22 Agriculture Victoria Services Pty Limited Uso de angiogenina no preparo de uma composição, suplemento alimentar ou nutracêutico para promover o crescimento e melhora muscular
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0958825A1 (fr) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Composition synergique à activité anticancéreuse à base de carbohydrates non digestibles et d'un médicament anti-cancéreux
ATE324801T1 (de) * 1999-09-06 2006-06-15 Guenther Beisel Vernetztes mittel zur erzeugung eines langanhaltenden sättigungseffekts und verfahren zu dessen herstellung
ATE532524T1 (de) * 2001-03-27 2011-11-15 Pro Pharmaceuticals Inc Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs
KR20040045795A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer

Also Published As

Publication number Publication date
BRPI0512394A (pt) 2008-03-11
CN101267828A (zh) 2008-09-17
WO2006002106A2 (fr) 2006-01-05
EP1765365A4 (fr) 2008-02-20
EP1765365A2 (fr) 2007-03-28
JP2008503583A (ja) 2008-02-07
CA2570570A1 (fr) 2006-01-05

Similar Documents

Publication Publication Date Title
Vogus et al. A review on engineering polymer drug conjugates to improve combination chemotherapy
WO2001012199A3 (fr) Effet synergique de la methoxyamide sur l'activite anticancereuse de la temozolomide
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
WO2004073656A3 (fr) Conjugues de medicaments anticorps anti-cd70, utilisation desdits conjugues dans le traitement du cancer et des troubles immunitaires
WO2002020663A3 (fr) Polymeres degradables de polyacetal
NO20013402D0 (no) Fremgangsmåter for behandling av ovarialcancer, poly(fosfoester)preparater, og bionedbrytbare gjenstander for detsamme
NZ590569A (en) Factor viii polymer conjugates
WO2004018000A3 (fr) Compositions et methodes de traitement du cancer a l'aide d'immunoconjugues cytotoxiques d'anticorps du cd44 et d'agents chimiotherapeutiques
NZ588913A (en) Liver cancer drug
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
AU3957400A (en) Dry, mouldable drug formulation
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2009140675A3 (fr) Thérapie combinée comportant un alcaloïde antitumoral
WO2001062235A3 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
WO2008002460A3 (fr) Composés antinéoplasiques indépendants de la lumière disponibles sous une forme orale
EP1140198A4 (fr) Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
WO2005025501A3 (fr) Co-administration de polysaccharide avec un agent chimiotherapeutique pour le traitement du cancer
Shahab et al. Vascular toxicity of antineoplastic agents
WO2006002106A3 (fr) Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide
WO2003097106A3 (fr) Medicaments
WO2007146417A3 (fr) Compositions de glucane et procédés destinés à accroître la cytotoxicité induite par les neutrophiles dépendants de cr3
WO2008089185A3 (fr) Conjugués posaconazole-polymère et méthodes de traitement au moyen de posaconazole et de conjugués polymères contenant cette substance
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
Rosenthal et al. Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil
WO2005002516A3 (fr) Conjugues peptides-medicaments integres dans des leucocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2570570

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005786102

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007518186

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580020707.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005786102

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512394

Country of ref document: BR